​

Quest Diagnostics (DGX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DGX Stock Forecast

Quest Diagnostics (DGX) stock forecast, based on 29 Wall Street analysts, predicts a 12-month average price target of $180.25, with a high of $195.00 and a low of $165.00. This represents a 9.59% increase from the last price of $164.47.

$120 $135 $150 $165 $180 $195 High: $195 Avg: $180.25 Low: $165 Last Closed Price: $164.47

DGX Stock Rating

Quest Diagnostics stock's rating consensus is Hold, based on 29 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (44.83%), 14 Hold (48.28%), 2 Sell (6.90%), and 0 Strong Sell (0.00%).

Hold
Total 29 0 2 14 13 Strong Sell Sell Hold Buy Strong Buy

DGX Price Target Upside V Benchmarks

TypeNameUpside
StockQuest Diagnostics9.59%
SectorHealthcare Stocks 33.91%
IndustryDiagnostics & Research Stocks45.48%

Price Target Trends

1M3M12M
# Anlaysts1414
Avg Price Target$195.00$186.50$171.79
Last Closing Price$164.47$164.47$164.47
Upside/Downside18.56%13.39%4.45%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 251710--18
Mar, 25189--18
Feb, 25189--18
Jan, 25199--19
Dec, 241810--19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 02, 2025Jamie ClarkRedburn Partners$195.00$167.9616.10%18.56%
Feb 03, 2025David WestenbergPiper Sandler$180.00$162.4710.79%9.44%
Jan 31, 2025David MacDonaldTruist Financial$182.00$163.1011.59%10.66%
Jan 31, 2025Eric ColdwellRobert W. Baird$189.00$163.1015.88%14.91%
Oct 23, 2024Patrick DonnellyCitigroup$185.00$157.4717.48%12.48%
Oct 23, 2024Michael ChernyLeerink Partners$165.00$157.474.78%0.32%
Oct 23, 2024Stephanie DavisBarclays$168.00$157.476.69%2.15%
Oct 23, 2024Eric ColdwellRobert W. Baird$182.00$157.4715.58%10.66%
Oct 22, 2024Paige MeyerCFRA$178.00$157.4613.04%8.23%
Oct 07, 2024David MacDonaldTruist Financial$165.00$150.799.42%0.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 04, 2025CitigroupBuyNeutraldowngrade
Oct 23, 2024CitigroupBuyBuyhold
Oct 23, 2024Leerink PartnersMarket PerformMarket Performhold
Oct 23, 2024BarclaysEqual-WeightEqual-Weighthold
Aug 27, 2024BarclaysEqual-WeightEqual-Weighthold
Jul 29, 2024Piper SandlerNeutralNeutralhold
Jul 15, 2024Zacks Investment ResearchBuyBuyhold
Jul 10, 2024CitigroupNeutralBuyupgrade
Jun 13, 2024CitigroupNeutralNeutralhold
May 30, 2024UBSBuyBuyhold

Financial Forecast

EPS Forecast

$7 $8 $9 $10 $11 $12 $13 $14 $15 $16 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.68$15.90$8.12$7.59$7.80----
Avg Forecast$10.80$14.12$9.85$8.71$8.90$9.73$10.51$11.56$12.71
High Forecast$11.33$14.81$10.03$8.75$8.93$9.77$12.37$12.45$13.00
Low Forecast$10.32$13.49$9.53$8.68$8.87$9.70$9.86$10.67$12.13
Surprise %-1.11%12.61%-17.56%-12.86%-12.36%----

Revenue Forecast

$9B $10B $10B $11B $12B $13B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.44B$10.79B$9.88B$9.25B$9.87B----
Avg Forecast$9.34B$10.74B$9.83B$9.22B$9.83B$10.71B$11.13B$11.68B$12.06B
High Forecast$9.70B$11.15B$9.97B$9.24B$9.84B$10.84B$11.17B$11.88B$12.27B
Low Forecast$9.02B$10.37B$9.58B$9.20B$9.81B$10.50B$11.10B$11.49B$11.63B
Surprise %1.01%0.44%0.54%0.39%0.43%----

Net Income Forecast

$500M $900M $1B $2B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.43B$2.00B$946.00M$854.00M$871.00M----
Avg Forecast$1.30B$1.71B$1.31B$850.00M$1.01B$1.10B$1.26B$1.38B$1.44B
High Forecast$1.56B$2.06B$1.57B$1.02B$1.01B$1.10B$1.40B$1.41B$1.47B
Low Forecast$1.04B$1.37B$1.04B$680.00M$1.00B$1.10B$1.11B$1.21B$1.37B
Surprise %9.82%16.48%-27.57%0.47%-13.39%----

DGX Forecast FAQ

Is Quest Diagnostics stock a buy?

Quest Diagnostics stock has a consensus rating of Hold, based on 29 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 14 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Quest Diagnostics is a neutral investment for most analysts.

What is Quest Diagnostics's price target?

Quest Diagnostics's price target, set by 29 Wall Street analysts, averages $180.25 over the next 12 months. The price target range spans from $165 at the low end to $195 at the high end, suggesting a potential 9.59% change from the previous closing price of $164.47.

How does Quest Diagnostics stock forecast compare to its benchmarks?

Quest Diagnostics's stock forecast shows a 9.59% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the diagnostics & research stocks industry (45.48%).

What is the breakdown of analyst ratings for Quest Diagnostics over the past three months?

  • April 2025: 5.56% Strong Buy, 38.89% Buy, 55.56% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 5.56% Strong Buy, 44.44% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 5.56% Strong Buy, 44.44% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Quest Diagnostics’s EPS forecast?

Quest Diagnostics's average annual EPS forecast for its fiscal year ending in December 2025 is $9.73, marking a 24.74% increase from the reported $7.8 in 2024. Estimates for the following years are $10.51 in 2026, $11.56 in 2027, and $12.71 in 2028.

What is Quest Diagnostics’s revenue forecast?

Quest Diagnostics's average annual revenue forecast for its fiscal year ending in December 2025 is $10.71B, reflecting a 8.47% increase from the reported $9.87B in 2024. The forecast for 2026 is $11.13B, followed by $11.68B for 2027, and $12.06B for 2028.

What is Quest Diagnostics’s net income forecast?

Quest Diagnostics's net income forecast for the fiscal year ending in December 2025 stands at $1.1B, representing an 26.27% increase from the reported $871M in 2024. Projections indicate $1.26B in 2026, $1.38B in 2027, and $1.44B in 2028.